Orthofix Medical (OFIX)

• Market cap: $504M
• 1 day: -0.84%
• 5 days: -7.45%
• 1 month: -22.31%
• 3 months: -29.63%
• 6 months: -20.25%
• Year to date: -25.14%
• 1 year: -1.22%
• 5 years: -59.17%
• 10 years: -64.53%
• Sector: Healthcare
• Industry: Medical Devices

About: Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Employees: 1,616

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 40

25% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]

7% more capital invested

Capital invested by funds: $542M [Q3] → $577M (+$35.4M) [Q4]

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 149 [Q3] → 149 (+0) [Q4]

0% more call options, than puts

Call options by funds: $7K | Put options by funds: $7K

4.33% less ownership

Funds ownership: 90.82% [Q3] → 86.49% (-4.33%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 70% upside
• Avg. target: $23 78% upside
• High target: $24 86% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Burrows 46% 1-year accuracy 12 / 26 met price target	86% upside $24	Buy Maintained	26 Feb 2025
Roth MKM Jason Wittes 38% 1-year accuracy 8 / 21 met price target	70% upside $22	Buy Reiterated	26 Feb 2025